ARWR Stock Price Today (October 2026) — Arrowhead Pharmaceuticals, Inc. Analysis & Key Metrics 2026-10-21
Arrowhead Pharmaceuticals, Inc. (ARWR) is trading at $58.92, up 2.95% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $107.36 (82.2% upside).
- Volatility is moderate (33.22% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (171.00% YoY) alongside competitive pressures in the Biotechnology space.
ARWR Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Arrowhead Pharmaceuticals, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $8.10B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+82.2% upside potential
Key Investor Questions About ARWR
What investors need to know before buying
Based on current market data, ARWR presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 36.80)
- Fundamentals say: Caution warranted (high leverage concerns)
ARWR's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ARWR investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.38B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ARWR stock traded between $36.57 and $95.49 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 33.22% annualized volatility and β=1.68, the stock exhibits high sensitivity to market moves—making ARWR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says
Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $109 From $63, Maintains Buy Rating
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Latest TickZen Insights
All insights →No TickZen article on ARWR yet. Our newest analysis:
Explore More Analysis for ARWR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 23, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $58.92. The RSI (14-day) is at 36.8, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $107.36 implies 82.2% upside from current levels. Volatility is moderate at 33.2% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Arrowhead Pharmaceuticals, Inc. (ARWR): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 24.46. Price-to-Sales is 17.02. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 14 analysts covering ARWR, the consensus price target is $107.36. This represents a 82.2% upside from the current price of $58.92. The range spans from a low target of $74.00 to a high target of $126.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Arrowhead Pharmaceuticals, Inc. (ARWR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Arrowhead Pharmaceuticals, Inc. (ARWR) investors include: 1. Moderate volatility (33.2% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 2.96x) which could pressure margins in a rising rate environment. 3. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 4. Elevated short interest (10.6% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Arrowhead Pharmaceuticals, Inc.'s (ARWR) current debt and financial health profile: Total debt stands at $1.38B. The debt-to-equity ratio is 2.96x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 5.90, indicating strong short-term liquidity. The quick ratio is 5.71. The company holds $1.60B in cash and equivalents. Free cash flow is negative at -$48.63M, which could limit the company's ability to manage debt obligations.